Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.58 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.58 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.58 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70027 | 0.91 | NPSR1 (0.67) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL4076254 | 0.86 | NPSR1 (0.53) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL12319273 | 0.85 | NPSR1 (0.56) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL1303016 | 0.84 | NPSR1 (0.60) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL2872059 | 0.83 | GSK3B (0.67) | LMNANPSR1GSK3BL3MBTL1TSHR | |
| SCHEMBL25075387 | 0.81 | NPSR1 (0.56) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL28643715 | 0.81 | NPSR1 (0.56) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL1587055 | 0.81 | NPSR1 (0.56) | LMNANPSR1PPARGNCOA2NCOA1 | |
| Hydrazine SCHEMBL27261279 | 0.81 | NPSR1 (0.56) | LMNANPSR1PPARGNCOA2NCOA1 | |
| SCHEMBL12319403 | 0.80 | NPSR1 (0.51) | LMNANPSR1PPARGNCOA2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2023-07-04 | — | — | US | disclosed |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2022-11-17 | — | — | US | disclosed |
| US-11034666-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2021-06-15 | — | — | US | disclosed |
| CN-112300149-A | Preparation method of arotinolol hydrochloride | 北京弘德信医药科技有限公司 | 2021-02-02 | — | — | CN | disclosed |
| CN-110372692-B | Dihydroquinazolinone reverse transport process blocker, and preparation method and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2020-10-23 | — | — | CN | disclosed |
| US-20200299256-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | AVEXXIN AS (NO) | 2020-09-24 | — | — | US | disclosed |
| EP-3283464-B1 | FACTOR XIA INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-23 | — | — | EP | disclosed |
| US-10259801-B2 | Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds | AVEXXIN AS (NO) | 2019-04-16 | — | — | US | disclosed |
| US-10081617-B2 | Factor XIa inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-09-25 | — | — | US | disclosed |
| US-20050209284-A1 | Tec kinase inhibitors | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005079791-A1 | THIOPHENE -2- CARBOXYLIC ACID - (1H - BENZIMIDAZOL - 2 YL) - AMIDE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE TEC KINASE ITK (INTERLEUKIN -2- INDUCIBLE T CELL KINASE) FOR THE TREATMENT OF INFLAMMATION, IMMUNOLOGICAL AND ALLERGIC DISORDERS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| EP-1289980-B1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2004-11-17 | — | — | EP | disclosed |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-05 | — | — | US | disclosed |
| EP-1382603-A1 | NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF | Eisai Co., Ltd. (JP) | 2004-01-21 | — | — | EP | disclosed |
| CN-1440400-A | Bicyelyl or heterobicyclylmethanesulfonylamino-substituted N-hydroxyformamides | SMITHKLINE BEECHAMP P L C (GB) | 2003-09-03 | — | — | CN | disclosed |
| EP-1289980-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM PLC (GB) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001090100-A1 | BICYCLYL OR HETEROBICYCLYLMETHANESULFONYLAMINO-SUBSTITUTED N-HYDROXYFORMAMIDES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-11-29 | — | — | WO | disclosed |
| US-5354754-A | Antitumor and -carcinogenic agents; treating human epidermoid carcinoma KB | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-10-11 | — | — | US | disclosed |
| EP-0418924-A2 | Pyrrolopyrimidines, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034666-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, OXER1, IL1B | LMNA 3329/4885NPSR1 2338/4885PPARG 2215/4885 |
| US-10259801-B2 | Anti-inflammatory and antitumor 2-oxothiazoles ABD 2-oxothiophenes compounds | OXER1, CCL2, IL6 | LMNA 4277/4885NPSR1 3456/4885PPARG 2274/4885 |
| US-20200299256-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | CASP1, OXER1, IL1B | LMNA 3301/4885NPSR1 2312/4885PPARG 2220/4885 |
| US-20220363659-A1 | ANTI-INFLAMMATORY AND ANTITUMOR 2-OXOTHIAZOLES AND 2-OXOTHIOPHENES COMPOUNDS | OXER1, CASP1, IL6 | LMNA 3479/4885NPSR1 2549/4885PPARG 2269/4885 |
| US-20040024066-A1 | Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides | CD22, CD2, NEU3 | LMNA 3270/4885NPSR1 1061/4885PPARG 4630/4885 |
| US-11691959-B2 | Anti-inflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds | CASP1, IL1B, OXER1 | LMNA 2661/4885NPSR1 2413/4885PPARG 2359/4885 |
| US-20050209284-A1 | Tec kinase inhibitors | TEC, ITK, TXK | LMNA 3906/4885NPSR1 3361/4885PPARG 3568/4885 |
| US-10081617-B2 | Factor XIa inhibitors | F11, F2, TFPI | LMNA 373/4885NPSR1 3450/4885PPARG 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.